{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:21:11Z","timestamp":1791472871648,"version":"4.3.4"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Several single-center studies have suggested that higher doses of vancomycin, aimed at producing trough concentrations of &gt;15 mg\/liter, are associated with increased risk of nephrotoxicity. We prospectively assessed the relative incidence of nephrotoxicity in relation to trough concentration in patients with documented methicillin-resistant\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Staphylococcus aureus<\/jats:named-content>\n                    (MRSA) infections at seven hospitals throughout South Carolina. Adult patients receiving vancomycin for at least 72 h with at least one vancomycin trough concentration determined under steady-state conditions were prospectively studied. The relationship between vancomycin trough concentrations of &gt;15 mg\/ml and the occurrence of nephrotoxicity was assessed using univariate and multivariate analyses, controlling for age, gender, race, dose, length of therapy, use of other nephrotoxins (including contrast media), intensive care unit (ICU) residence, episodes of hypotension, and comorbidities. Nephrotoxicity was defined as an increase in serum creatinine of 0.5 mg\/dl or a \u226550% increase from the baseline for two consecutive measurements. MICs of vancomycin for the MRSA isolates were also determined. A total of 288 patients were studied between February 2008 and June 2010, with approximately one-half having initial trough concentrations of \u226515 mg\/ml. Nephrotoxicity was observed for 42 patients (29.6%) with trough concentrations &gt;15 mg\/ml and for 13 (8.9%) with trough concentrations of \u226415 mg\/ml. Multivariate analysis revealed vancomycin trough concentrations of &gt;15 mg\/ml and race (black) as risk factors for nephrotoxicity in this population. Vancomycin trough concentrations of &gt;15 mg\/ml appear to be associated with a 3-fold increased risk of nephrotoxicity.\n                  <\/jats:p>","DOI":"10.1128\/aac.00168-11","type":"journal-article","created":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T23:50:46Z","timestamp":1317081046000},"page":"5475-5479","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":211,"title":["Relationship between Vancomycin Trough Concentrations and Nephrotoxicity: a Prospective Multicenter Trial"],"prefix":"10.1128","volume":"55","author":[{"given":"John A.","family":"Bosso","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy and Outcome Sciences, South Carolina College of Pharmacy, Charleston and Columbia, South Carolina"},{"name":"Division of Infectious Diseases, Medical University of South Carolina College of Medicine, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Nappi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcome Sciences, South Carolina College of Pharmacy, Charleston and Columbia, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Rudisill","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcome Sciences, South Carolina College of Pharmacy, Charleston and Columbia, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlea","family":"Wellein","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Trident Medical Center, Charleston, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Brandon","family":"Bookstaver","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcome Sciences, South Carolina College of Pharmacy, Charleston and Columbia, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Swindler","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, McLeod Regional Medical Center, Florence, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D.","family":"Mauldin","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Outcome Sciences, South Carolina College of Pharmacy, Charleston and Columbia, South Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/501641"},{"key":"e_1_3_2_3_2","unstructured":"Centers for Disease Control Prevention. Accessed 9 December 2010. Active bacterial core surveillance (ABCs) report emerging infections program network methicillin-resistant Staphylococcus aureus 2008. http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/mrsa08.html."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/381093"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/345476"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5520(03)00065-5"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/367653"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2005.09.006"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01088-08"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-2453"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.2.182"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.19.2138"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/591861"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.06.014"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1115"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/587673"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.15.1763"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir124"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00113-08"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01602-07"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn329"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/600884"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.08.003"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443130-00005"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.15.1756"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir078"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.07.025"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/430175"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/491712"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp080434"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00093-09"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.6.2398-2402.2004"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm258"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-5-2"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01388-06"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.10.013"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00168-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00168-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T18:21:07Z","timestamp":1645467667000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00168-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["10.1128\/AAC.00168-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.00168-11","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13396971.14765089","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"2011-02-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-09-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-11-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}